Evidence map›Paper›PMID 10603399›Full record

ArticleInfection and immunity2000

Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.

M Martin, D J Metzger, S M Michalek, T D Connell, M W Russell

Open access · greenAbstract readComparative Study
In one paragraph

Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

M MartinDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. michmart@uab.edu
D J Metzger
S M Michalek
T D Connell
M W Russell
University of Alabama at Birmingham · USUniversity at Buffalo, State University of New York · US

Funding

IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
Genetically Engineered Oral Vaccines &Caries ImmunityR01DE009081 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHALEK, SUZANNE M. · 1990 to 2012
$3.2M
ANTIGENS OF STREPTOCOCCUS MUTANS IN CARIES IMMUNITYR37DE006746 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RUSSELL, MICHAEL W · 1999 to 2008
$2.4M
REGULATION OF IMMUNE RESPONSES IN THE ORAL CAVITYR01DE008182 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHALEK, SUZANNE M. · 1988 to 2003
$972k
PROTEIN ANTIGENS OF STREP MUTANS IN CARIES IMMUNITYR01DE006746 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RUSSELL, MICHAEL W · 1985 to 1998
–
NIAID NIH HHS T32 AI007051NIDCR NIH HHS DE 06746NIDCR NIH HHS DE 08182NIDCR NIH HHS DE 09081NIDCR NIH HHS R01 DE008182NIDCR NIH HHS R01 DE009081NIDCR NIH HHS R37 DE006746
6 · The paper itself

Abstract

Cholera toxin (CT) and the heat-labile enterotoxin of Escherichia coli (LT-I) are members of the serogroup I heat-labile enterotoxins (HLT) and can serve as systemic and mucosal adjuvants. However, information is lacking with respect to the structurally related but antigenically distinct serogroup II HLT, LT-IIa and LT-IIb, which have different binding specificities for ganglioside receptors. The purpose of this study was to assess the effectiveness of LT-IIa and LT-IIb as mucosal adjuvants in comparison to the prototypical type I HLT, CT. BALB/c mice were immunized by the intranasal (i.n.) route with the surface protein adhesin AgI/II of Streptococcus mutans alone or supplemented with an adjuvant amount of CT, LT-IIa, or LT-IIb. Antigen-specific antibody responses in saliva, vaginal wash, and plasma were assayed by enzyme-linked immunosorbent assay. Mice given AgI/II with LT-IIa or LT-IIb by the i.n. route had significantly higher mucosal and systemic antibody responses than mice immunized with AgI/II alone. Anti-AgI/II immunoglobulin A (IgA) antibody activity in saliva and vaginal secretions of mice given AgI/II with LT-IIa or LT-IIb was statistically similar in magnitude to that seen in mice given AgI/II and CT. LT-IIb significantly enhanced the number of AgI/II-specific antibody-secreting cells in the draining superficial cervical lymph nodes compared to LT-IIa and CT. LT-IIb and CT induced significantly higher plasma anti-AgI/II IgG titers compared to LT-IIa. When LT-IIb was used as adjuvant, the proportion of plasma IgG2a relative to IgG1 anti-AgI/II antibody was elevated in contrast to the predominance of IgG1 antibodies promoted by AgI/II alone or when CT or LT-IIa was used. In vitro stimulation of AgI/II-specific cells from the superficial lymph nodes and spleen revealed that LT-IIa and LT-IIb induced secretion of interleukin-4 and significantly higher levels of gamma interferon compared to CT. These results demonstrate that the type II HLT LT-IIa and LT-IIb exhibit potent and distinct adjuvant properties for stimulating immune responses to a noncoupled protein immunogen after mucosal immunization.

Indexed as

Escherichia coli ProteinsImmunity, MucosalAdhesins, BacterialAdjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, BacterialAntibody-Producing CellsBacterial ToxinsCholera ToxinCytokinesEnterotoxinsEscherichia coliFemaleImmunity, CellularImmunizationAdhesins, BacterialAdjuvants, ImmunologicAntibodies, BacterialBacterial ToxinsCholera ToxinCytokinesEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliImmunoglobulin AImmunoglobulin G

Identifiers

PMID10603399
PMCPMC97132
OpenAlexW2162425865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.